Status and phase
Conditions
Treatments
About
Full description
Safety
Incidence of fever (temperature ≥39.0℃) within 42 days after the IP administration Incidence of fever (temperature ≥39.0℃) within 7 days after the IP administration Solicited local/systemic AEs occurred within 7 days after the IP administration Unsolicited adverse events that occurred within 42 days after the IP administration Serious adverse events that occurred within 1 year after the IP administration Vital signs and physical examinations
Efficacy (Immunogenicity)
-GMT(Geometric Mean Titer) and GMR(Geometric Mean Ratio(fold change))measured by the glycoprotein enzyme-linked immunosorbent assay (gpELISA) at before and 42 days after the IP administration
Exploratory assessment
GMV and GMR of VZV-CMI response measured by INF-r ELISPOT at before and 42 days after the IP administration GMT and GMR of the antibody titer measured by gpELISA at before and after the IP administration for 3 years Varicella-like rash and Varicella-zoster virus genotyping analysis occurred after IP administration for 3 years
Enrollment
Sex
Ages
Volunteers
Inclusion criteria
Exclusion criteria
Primary purpose
Allocation
Interventional model
Masking
230 participants in 3 patient groups
Loading...
Central trial contact
Hye Won Shin
Data sourced from clinicaltrials.gov
Clinical trials
Research sites
Resources
Legal